Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRS3 | P32247 | 1/20 | 0.48 |
| ▸ | RORC | P51449 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | MITF | O75030 | 1/20 | 0.36 |
| ▸ | PTPRB | P23467 | 1/20 | 0.36 |
| ▸ | ELANE | P08246 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.35 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL992226 | 0.86 | RORC (0.50) | BRS3RORCCNR2MITFELANE | |
| SCHEMBL992252 | 0.85 | HRH3 (0.41) | MITFELANECA1CA2 | |
| SCHEMBL28575707 | 0.82 | BRS3 (0.43) | BRS3RORCCNR1CNR2 | |
| SCHEMBL3587301 | 0.80 | MITF (0.53) | MITFCA1CA2GRIA4EPHX2 | |
| SCHEMBL30334488 | 0.79 | BRS3 (0.50) | BRS3RORCCNR1CNR2EPHX2 | |
| SCHEMBL3656294 | 0.79 | CYP4A11 (0.54) | BRS3CNR1CNR2CA1CA2 | |
| SCHEMBL28758271 | 0.79 | BRS3 (0.54) | BRS3RORCCNR1CNR2CA1 | |
| SCHEMBL7044989 | 0.78 | ACACB (0.38) | BRS3CNR1CNR2ELANE | |
| SCHEMBL3258334 | 0.78 | CA2 (0.50) | MITFCA1CA2 | |
| SCHEMBL21629639 | 0.77 | BRS3 (0.53) | BRS3RORCCNR1CNR2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130116439-A1 | PROCESS FOR PREPARATION OF 2-METHYL-2'-PHENYLPROPIONIC ACID DERIVATIVES AND NOVEL INTERMEDIATE COMPOUNDS | YUHAN CORPORATION (KR) | 2013-05-09 | — | — | US | disclosed |
| EP-2240464-A2 | PROCESS FOR PREPARATION OF 2-METHYL-2´-PHENYLPROPIONIC ACID DERIVATIVES AND NOVEL INTERMEDIATE COMPOUNDS | Yuhan Corporation (KR) | 2010-10-20 | — | — | EP | disclosed |
| WO-2009102155-A2 | PROCESS FOR PREPARATION OF 2-METHYL-2´-PHENYLPROPIONIC ACID DERIVATIVES AND NOVEL INTERMEDIATE COMPOUNDS | YUHAN CORPORATION (KR) | 2009-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116439-A1 | PROCESS FOR PREPARATION OF 2-METHYL-2'-PHENYLPROPIONIC ACID DERIVATIVES AND NOVEL INTERMEDIATE COMPOUNDS | HRH2, HRH4, HNMT | BRS3 1384/4885RORC 3248/4885CNR1 1009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.